| High Grade B-Cell Lymphoma studied in …STUDIED_INderived142 of 142show fewer |
|---|
| → studied in | NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03418038Phase 2 · recruiting Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia · condition mapped ONTOLOGY_EXACT · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05600686Phase 2 · active not recruiting Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04594642Phase 1 · active not recruiting A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06830031Phase 1 · recruiting Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07098364Phase 1/Phase 2 · suspended ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07814001Phase 2 · not yet recruiting Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03625037Phase 1/Phase 2 · active not recruiting First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04542824Phase 1/Phase 2 · active not recruiting Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07225439Phase 1 · recruiting Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502872Phase 2 · not yet recruiting TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784726Phase 2 · recruiting Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07365306Phase 2 · recruiting Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06536049Phase 1/Phase 2 · recruiting Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07724457Phase 2/Phase 3 · not yet recruiting Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07774234Phase 2 · not yet recruiting Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07735533Phase 1/Phase 2 · not yet recruiting A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07649304Phase 1 · not yet recruiting AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03136146Phase 2 · recruiting Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05075603Phase 1 · completed Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03656835NA · active not recruiting Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06533579Phase 1/Phase 2 · recruiting Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07750886recruiting Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06116110recruiting Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03984448Phase 2/Phase 3 · active not recruiting Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07069699Phase 1/Phase 2 · recruiting Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene · condition mapped ONTOLOGY_EXACT · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02727803Phase 2 · recruiting Personalized NK Cell Therapy in CBT · condition mapped ONTOLOGY_EXACT · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07197307Phase 2 · recruiting Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06765317Phase 2 · recruiting A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05660395Phase 1 · terminated A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714421Phase 1 · not yet recruiting Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01371630Phase 1/Phase 2 · recruiting Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04792489Phase 2 · recruiting DALY II USA/ MB-CART2019.1 for DLBCL · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05077527Phase 1 · recruiting Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672251Phase 2 · recruiting Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06015880Phase 1 · recruiting Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06249191Phase 1/Phase 2 · recruiting Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04836507Phase 1/Phase 2 · recruiting Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05653271Phase 1 · completed ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06905509Phase 2 · recruiting Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04257578Phase 1/Phase 2 · active not recruiting Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455697Phase 1/Phase 2 · active not recruiting Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06703892Phase 1 · recruiting A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06985576enrolling by invitation Long-term Study to Evaluate Safety and Persistence of GF-CART01 · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07638982Phase 1 · not yet recruiting Axatilimab + CAR-T for High-Risk Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06271057Phase 2 · recruiting Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05412290Phase 1 · active not recruiting Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05418088Phase 1 · recruiting Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06458439Phase 2 · recruiting Epcoritamab-CAR T Cells for Large B-cell Lymphomas · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03038672Phase 2 · active not recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06014762Phase 1 · active not recruiting P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07552324Phase 2 · not yet recruiting Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP · condition mapped ALIAS · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07097363Phase 2 · recruiting Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05507541Phase 2 · active not recruiting TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05757700Phase 1 · active not recruiting Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06544265Phase 1 · recruiting SynKIR-310 for Relapsed/Refractory B-NHL · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04300998recruiting Study of CAR-T Therapy in Older Patients · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06208735Phase 1 · recruiting CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07502118Phase 2/Phase 3 · recruiting NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06026319Phase 1 · recruiting CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07473167Phase 1/Phase 2 · recruiting Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma Patients · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07463781not yet recruiting Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell Therapy · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05256641Phase 1/Phase 2 · recruiting Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07042438Phase 2 · recruiting Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T Cells · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205838Phase 2 · terminated Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05755087Phase 1 · recruiting Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04512716early Phase 1 · recruiting Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05544019Phase 1 · recruiting Study of SGR-1505 in Mature B-Cell Neoplasms · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04067414Phase 1 · completed Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03749018Phase 2 · active not recruiting Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04323956Phase 1 · active not recruiting Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04285268Phase 2 · withdrawn Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04745559Phase 2 · active not recruiting Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583149Phase 2 · active not recruiting Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06834373Phase 2 · recruiting Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06693830NA · recruiting ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04855253Phase 1/Phase 2 · suspended Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05464329Phase 1 · active not recruiting Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06588205recruiting Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05619367available A Compassionate Use (CU) Program of Odronextamab · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06736613Phase 2 · recruiting A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06004167NA · completed Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06550141Phase 2 · recruiting Emapalumab Prevention of CAR-T Cell Associated Toxicities · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05890352Phase 2 · recruiting Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02153580Phase 1 · active not recruiting Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04479267Phase 2 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05621096Phase 1 · active not recruiting Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06343311Phase 1/Phase 2 · recruiting T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06343376Phase 1 · terminated Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742258Phase 1 · completed Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03995147Phase 2 · active not recruiting Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05908409Phase 1/Phase 2 · recruiting A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06918912Phase 2 · recruiting Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06093841Phase 2 · active not recruiting Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04432506Phase 2 · completed Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06796517recruiting Immunotherapy in Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05263583Phase 2 · active not recruiting Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04358458Phase 1/Phase 2 · terminated First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05202782Phase 2 · active not recruiting Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04914741Phase 1/Phase 2 · unknown A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06287398Phase 2 · recruiting Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04555811Phase 1 · completed FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04933617Phase 1 · terminated Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02199184Phase 2 · completed Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02348216Phase 1/Phase 2 · completed Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03103971Phase 1 · terminated huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03620578Phase 2 · active not recruiting DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04858568completed Immune Responses to COVID-19 Vaccination in Lymphoma Patients · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04220008Phase 2 · withdrawn Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04870853unknown Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03309878Phase 1/Phase 2 · completed Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04409314completed Hypoxia-Specific Imaging to Predict Outcomes of Chimeric Antigen Receptor T-cell Therapy · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05974085Phase 2 · unknown XPO-1 in Combination With RCHOP for DH/TH Lymphoma · condition mapped ALIAS · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05834426unknown Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05733650approved for marketing Expanded Access Program for Epcoritamab · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05228249Phase 1 · withdrawn Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01859819Phase 2 · completed Treatment for Advanced B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02706405Phase 1 · terminated JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03036904Phase 1 · completed Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04226937unknown DLBCL Interim Response Evaluation for Customised Therapy · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04844086Phase 1 · terminated RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04058470Phase 1/Phase 2 · unknown Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02481310Phase 1/Phase 2 · unknown Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma · condition mapped ALIAS · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03837873Phase 2 · unknown DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03255096Phase 1 · completed A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03629873Phase 2 · unknown Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects · condition mapped ALIAS · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05164770Phase 3 · unknown Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05097443Phase 3 · unknown Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01742988Phase 1 · completed Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04476459Phase 1/Phase 2 · unknown Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04796857Phase 1/Phase 2 · unknown Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04503538NA · withdrawn Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01619761Phase 1 · unknown NK Cells in Cord Blood Transplantation · condition mapped ONTOLOGY_EXACT · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01722305Phase 1 · completed Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma · condition mapped ALIAS · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01897012Phase 1 · completed Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03132584Phase 1 · terminated Cyclophosphamide and Alemtuzumab In Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02623920Phase 2 · withdrawn Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01809600completed Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults · condition mapped CURATED_BROADER · 142 trials mapped (91 active) | — | — | High Grade B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |